Albireo Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall St futures slip as yields and oil rebound; Fed minutes in focusĀ
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Musk rules out TSMC role in Terafab operations; Intel gains
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- HubSpot to cut 7% of workforce in restructuring plan
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Caribou Biosciences to halt CAR-T programs, explore sale
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- Francis Halzen wins Nobel physics prize for Antarctic 'ghost particle' hunt
Albireo Pharma (ALBO) Prices 1.97M Common Stock Offering at $33/Share
January 25, 2018 8:46 AM ESTAlbireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 1,970,000 shares of its common stock at a price to the public of $33.00 per share. Albireos gross proceeds from this offering... More



